External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry

Sophie E.M. Veldhuijzen van Zanten*, Adam Lane, Martijn W. Heymans, Joshua Baugh, Brooklyn Chaney, Lindsey M. Hoffman, Renee Doughman, Marc H.A. Jansen, Esther Sanchez, William P. Vandertop, Gertjan J.L. Kaspers, Dannis G. van Vuurden, Maryam Fouladi, Blaise V. Jones, James Leach

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


We aimed to perform external validation of the recently developed survival prediction model for diffuse intrinsic pontine glioma (DIPG), and discuss its utility. The DIPG survival prediction model was developed in a cohort of patients from the Netherlands, United Kingdom and Germany, registered in the SIOPE DIPG Registry, and includes age <3 years, longer symptom duration and receipt of chemotherapy as favorable predictors, and presence of ring-enhancement on MRI as unfavorable predictor. Model performance was evaluated by analyzing the discrimination and calibration abilities. External validation was performed using an unselected cohort from the International DIPG Registry, including patients from United States, Canada, Australia and New Zealand. Basic comparison with the results of the original study was performed using descriptive statistics, and univariate- and multivariable regression analyses in the validation cohort. External validation was assessed following a variety of analyses described previously. Baseline patient characteristics and results from the regression analyses were largely comparable. Kaplan–Meier curves of the validation cohort reproduced separated groups of standard (n = 39), intermediate (n = 125), and high-risk (n = 78) patients. This discriminative ability was confirmed by similar values for the hazard ratios across these risk groups. The calibration curve in the validation cohort showed a symmetric underestimation of the predicted survival probabilities. In this external validation study, we demonstrate that the DIPG survival prediction model has acceptable cross-cohort calibration and is able to discriminate patients with short, average, and increased survival. We discuss how this clinico-radiological model may serve a useful role in current clinical practice.

Original languageEnglish
Pages (from-to)231-240
Number of pages10
JournalJournal of Neuro-Oncology
Issue number1
Publication statusPublished - 1 Aug 2017

Cite this